PBYINasdaqPharmaceutical PreparationsFiscal year ends December 31
PUMA BIOTECHNOLOGY, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$10.21+0.38 (+3.87%)
Close on Oct 19, 2026
- Market cap
- $537.01M
- P/E (TTM)
- 19.6
- Dividend yield
- –
PUMA BIOTECHNOLOGY, INC. revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product [Member] | $53.56M | $41.96M | $59.88M | $51.90M | $49.19M | $43.10M | $54.38M | $56.14M | $44.40M | $40.28M | $53.17M | $51.59M | 94.8% | +8.9% |
| Royalty [Member] | $2.94M | $2.86M | $15.57M | $2.57M | $3.25M | $2.90M | $4.70M | $24.41M | $2.69M | $3.49M | $19.01M | $4.52M | 5.2% | -9.4% |
By region
From the segment and revenue-disaggregation notes of Puma Biotechnology's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.